Featured Articles

  1. Drug Repurposing Advantages And Strategies

    Identifying new therapeutic uses for old, existing, or available drugs is an effective strategy in discovering or developing drug molecules with new pharmacological and therapeutic indications.

  2. Supply Chain Transformation, 503B And Reducing Drug Shortages 9/11/2020

    Currently there are two great forces at work that are disrupting traditional models for advancing drug therapies from discovery to commercial production and distribution. This transformation, when complete, will impact the biopharmaceutical supply chain significantly and potentially achieve outcomes that were considered impossible a short time ago.

  3. Navigating An Ever-Changing Landscape: The Role Of A CFO In A Private Equity Controlled Pharma Company

    The role of Chief Financial Officer for a small-to-mid size pharma company controlled by private equity is a challenging one, especially since pharma companies with limited internal resources often rely on CDMOs for support. Learn how these CFOs can use their CDMOs to be more successful.

  4. CDMO Innovation For The Future Pharmaceutical Supply Chain

    We have a longstanding mantra, “challenges frame opportunities.” This applies to how we intentionally innovate, modernize, and introduce new capabilities and expand capacity.

  5. Self-Injection Of Biologics Made Easy 6/17/2022

    Ready-to-Use (RTU) 3mL cartridge-based, single-use Pen Devices are specifically designed to ensure consistency of delivery for high-volume, high-viscosity injectable drug delivery systems.

  6. Meet The Scientist — Sam Chia

    Sam is responsible for the sterile injectables facility, including four manufacturing suites and housing R&D, quality control, microbiology, and engineering support. He believes his role is most importantly about people – his colleagues and the patients who rely on the drug therapies they develop and manufacture.

  7. Demystifying Highly Potent API And Cytotoxic Drug Products

    The concept of development, process design, and manufacturing of drugs with a HPAPI or cytotoxic compounds should not be a mystery to drug sponsors using a CDMO. Gathering, organizing, and understanding critical risk data related to HPAPIs and cytotoxic drugs ensures appropriate controls are defined from concept to clinical batch manufacturing to commercial-scale manufacturing.

  8. Scaling Aseptic Pharmaceutical Production During Uncertainty

    Aseptic production and fill/finish operations are complex, and unexpected challenges should not disrupt the outcome of delivering needed pharmaceutical products to patients.

  9. Oxygen Sensitive Drug Products

    Primary packaging is thought of as the first line of defense against the negative effects of oxygen. This article highlights other areas to consider that can help avoid drug quality degradation.

  10. The Case For Repatriating The Pharmaceutical Supply Chain

    The pandemic has broadcast a loud call to bring our pharmaceutical supply chain back to the U.S. to provide greater regulatory control and patient, economic, and workforce benefits.